2026 Interim report
Filed with HKEX · Stock code 1801 · · 106 pages · English
Company Profile 2 Corporate Information 3 Financial Highlights 5 Business Highlights 8 Management Discussion and Analysis 14 Other Information 39 Report on Review of Condensed Consolidated Financial Statements 64 Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 65 Condensed Consolidated Statement of Financial Position 66 Condensed Consolidated Statement of Changes
Innovent Biologics, Inc. on 6ix
Earlier from Innovent Biologics
- Voluntary announcement - Jaypirca (pirtobrutinib) approved in China for a new indication in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) across all lines of therapy
- Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC
- Altruist Biologics' Suzhou Site Receives EMA GMP Certification, Enabling Product Commercialization for the European Market
- Innovent Announces 2026 Interim Results and Business Updates
- Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China
Later from Innovent Biologics
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Inside information announcement - product revenue in the third quarter of 2026
Follow Innovent Biologics into a list and get an email when it puts out news.
Follow Innovent Biologics